Targeting Mediator Kinase Attenuates Cardiac Hypertrophy by Regulating Enhancer Utilization
- 1University of Iowa
Abstract
BACKGROUND: Cardiac hypertrophy is characterized by extensive transcriptional remodeling that contributes to the progression of heart failure. Preclinical models demonstrate that therapies targeting hypertrophic responses can mitigate disease severity. Recent evidence shows that failing human and murine hearts exhibit elevated mediator kinase expression, sufficient to drive eccentric hypertrophy and heart failure through activation of hypertrophic gene programs. Mediator kinase inhibition suppresses oncogenic transcription by altering enhancer utilization, suggesting similar mechanisms may attenuate pathological remodeling in the heart. This study investigates whether mediator kinase inhibition can blunt cardiomyocyte hypertrophy, offering a potential therapeutic strategy for heart failure. METHODS: Two structurally unrelated mediator kinase inhibitors, Senexin A (SxnA) and CCT251545, were tested in neonatal rat cardiomyocytes. Hypertrophy was assessed by cell size measurements, RNA sequencing, and H3K27ac chromatin immunoprecipitation sequencing. RESULTS: Mediator kinase inhibition significantly reduced hypertrophic growth, attenuating cell size increases induced by phenylephrine (PE) and endothelin-1. Transcriptomic profiling revealed a dose-dependent suppression of PE-induced differentially expressed genes in Senexin A-treated cells. Mechanistically, PE stimulation enhanced RNA polymerase II pause release, whereas Mediator kinase inhibition did not alter this process. Epigenomic analysis showed that PE markedly increased the number of super-enhancers relative to vehicle treatment, while co-treatment with Senexin A reduced the total number of active enhancers. Nearest-neighbor analysis linked putative regulatory enhancers to key PE-responsive genes, and these enhancer signatures were blunted by SxnA. CONCLUSIONS: These findings demonstrate that Mediator kinase inhibition counteracts hypertrophic growth and transcriptional reprogramming, highlighting its potential as a therapeutic strategy to modulate pathological gene regulation in cardiac hypertrophy.
Related
- Gui Gan Shen Mai Yin attenuates cardiac hypertrophy and dysfunction in association with mitochondrial homeostasis and the PI3K/AKT1 signaling pathway
- Oral administration of Angiotensin-(1-7) included in hydroxypropyl β-cyclodextrin attenuates cardiac hypertrophy and inflammation in a mouse model of Takotsubo cardiomyopathy
- Postnatal deletion of Dlx5/6 in Osx-lineage cells drives bone hypertrophy by regulating osteoblast expansion and maturation
- Nicotinamide Mononucleotide Does Not Prevent Cardiac Hypertrophy but Attenuates Cardiac Stress and Remodeling Markers in Mice Exposed to Intermittent Normobaric Hypoxia
- Glycyrrhizic acid attenuates sepsis-induced acute lung injury by regulating macrophage M2 polarization via PRKCD
BibTeX
@article{minerath2026targeting,
title = {{Targeting Mediator Kinase Attenuates Cardiac Hypertrophy by Regulating Enhancer Utilization}},
author = {Rachel A. Minerath and Kayla M. Henry and Anna K. Leinheiser and Olha M. Koval and Allison M. Hagenow and Duane D. Hall and Colleen C. Mitchell and Chad E. Grueter},
journal = {Journal of the American Heart Association},
year = {2026},
month = oct,
doi = {10.1161/jaha.125.045861},
url = {https://www.ahajournals.org/doi/10.1161/JAHA.125.045861},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Targeting Mediator Kinase Attenuates Cardiac Hypertrophy by Regulating Enhancer Utilization
AU - Rachel A. Minerath
AU - Kayla M. Henry
AU - Anna K. Leinheiser
AU - Olha M. Koval
AU - Allison M. Hagenow
AU - Duane D. Hall
AU - Colleen C. Mitchell
AU - Chad E. Grueter
PY - 2026
DA - 2026/10/23
JO - Journal of the American Heart Association
DO - 10.1161/jaha.125.045861
UR - https://www.ahajournals.org/doi/10.1161/JAHA.125.045861
AB - BACKGROUND: Cardiac hypertrophy is characterized by extensive transcriptional remodeling that contributes to the progression of heart failure. Preclinical models demonstrate that therapies targeting hypertrophic responses can mitigate disease severity. Recent evidence shows that failing human and murine hearts exhibit elevated mediator kinase expression, sufficient to drive eccentric hypertrophy and heart failure through activation of hypertrophic gene programs. Mediator kinase inhibition suppresses oncogenic transcription by altering enhancer utilization, suggesting similar mechanisms may attenuate pathological remodeling in the heart. This study investigates whether mediator kinase inhibition can blunt cardiomyocyte hypertrophy, offering a potential therapeutic strategy for heart failure. METHODS: Two structurally unrelated mediator kinase inhibitors, Senexin A (SxnA) and CCT251545, were tested in neonatal rat cardiomyocytes. Hypertrophy was assessed by cell size measurements, RNA sequencing, and H3K27ac chromatin immunoprecipitation sequencing. RESULTS: Mediator kinase inhibition significantly reduced hypertrophic growth, attenuating cell size increases induced by phenylephrine (PE) and endothelin-1. Transcriptomic profiling revealed a dose-dependent suppression of PE-induced differentially expressed genes in Senexin A-treated cells. Mechanistically, PE stimulation enhanced RNA polymerase II pause release, whereas Mediator kinase inhibition did not alter this process. Epigenomic analysis showed that PE markedly increased the number of super-enhancers relative to vehicle treatment, while co-treatment with Senexin A reduced the total number of active enhancers. Nearest-neighbor analysis linked putative regulatory enhancers to key PE-responsive genes, and these enhancer signatures were blunted by SxnA. CONCLUSIONS: These findings demonstrate that Mediator kinase inhibition counteracts hypertrophic growth and transcriptional reprogramming, highlighting its potential as a therapeutic strategy to modulate pathological gene regulation in cardiac hypertrophy.
SN - 2047-9980
ER -